Matt Tabinor ن

Follower of Jesus ✝️, Husband and Father 👨‍👩‍👦, Kidney Doctor 🩺, Postgrad Research - Body Composition in CKD 💪🏼. 🇬🇧🎗️. All views are personal.

[CKJ @CKJsocial]

Pre-transplant and persistent post-transplant hyperparathyroidism and kidney transplant outcomes: a systematic review and meta-analysis

https://t.co/HeDBvj4gKw

[NDT @NDTsocial]

📹Watch Dr Daniel Kraus present the NDT publication:

Bleeding risk after kidney biopsy with platelet inhibition

👇👇👇
https://t.co/kHShx5iiqU

[The Lancet @TheLancet]

ICYMI: The INFINITY trial found that finerenone reduced the risk of chronic kidney disease progression, including kidney failure alone, and reduced heart failure hospitalisation, cardiovascular death, and all-cause death.

Read now: https://t.co/wJv3hM9wDE #ERA2026 @ERAKidney

[Abdelhamed Hamdy @Abdelhamed6261]

B cell depletion

[Brendon Neuen @brendonneuen]

Finerenone in CKD - an IPD-meta-analysis of FIND-CKD, FIDELIO-DKD and FIGARO-DKD (INFINITY)

Free open access link to the INFINITY analysis in the Lancet (link expires July 25) https://t.co/ag4H8Xkk5m

[The Lancet @TheLancet]

Chronic kidney disease is projected to become the 5th leading cause of death worldwide by 2040.

A new Editorial examines how better prevention, earlier detection, personalised care, and stronger health systems could transform outcomes for millions: https://t.co/PPol7CKGCN

[Brendon Neuen @brendonneuen]

Time to implement the #4pillars of “kidney GDMT”

- RAS blockade
- SGLT2i
- ns-MRA
- GLP-1 RA

Lifetime cardiovascular, kidney & mortality benefits of combination therapy in people with diabetes with albuminuria

Now #openaccess in @CircAHA for #AHA23

https://t.co/yRLSRlVujH

[Intissar HADDIYA @HaddiyaIntissar]

Lupus Nephritis in 4 Decades
🔹 1980s–1990s: Cyclophosphamide ->foundation of TRT
🔹 2000s: MMF ->alternative(ALMS, MAINTAIN)
🔹 2010s: B cell targeted approaches (LUNAR)
🔹 2020s: Combination therapies improved outcomes (BLISS LN, AURORA, REGENCY) @AfricanAFRAN @ISNkidneycare

[Ahmed Bennis MD 🫀 @drbennisahmed]

Quadruple GDMT for HFrEF — start all 4 on Day 1.
ARNi → 28% mortality ↓
BB → 34% mortality ↓
MRA → 25% mortality ↓
SGLT2i → 17% mortality ↓
Together: 73% all-cause mortality RRR. NNT = 3.9. Median survival extended 7–11 years.

#HFrEF #GDMT

[NDT @NDTsocial]

Cyclosporin A- versus tacrolimus-specific lesions in calcineurin inhibitor nephrotoxicity

📖https://t.co/YqWY38PW3c

[Ahmed Bennis MD 🫀 @drbennisahmed]

The evolving treatment paradigm for CKD — diabetic vs non-diabetic:
🔵 Diabetic KD: RASi + SGLT2i + Finerenone + GLP-1RA — 4-pillar approach
⚪ Non-diabetic KD: RASi + SGLT2i + Finerenone + aetiology-specific therapies + other treatments?

[ASN Publications @asnpublications]

New study in #ASNJASN published simultaneously with #ERA26 compared efficacy & safety of steady concentration PD using Carry Life UF system in home setting. Treatment resulted in higher UF volume, sodium removal, & glucose UF efficiency compared to 2.5% dextrose control https://t.co/l3ssh5Re9R

[ERA - European Renal Association @ERAkidney]

5/7 🧗Risk stratification in chronic kidney disease: outcomes using cystatin-C and creatinine based eGFR. #ERA26
🎤 Matthew Tabinor @Tabsinator

📊 CKD identified only by cystatin C carried a markedly higher risk of mortality and hospitalisation than creatinine-defined CKD.

⚠️ Yet >80% of these patients would have been excluded from major cardiorenal trials.

🧪 Cystatin C may improve CKD risk stratification beyond current creatinine-based definitions.

[ERA - European Renal Association @ERAkidney]

1/7✨A really “Challenging your thinking”session at #ERA26 this morning on

eGFR, Risk Equations and Prediction Models in CKD
🪑: Pierre Delanaye @PStoneOftheYear
🪑: Rouvik Gama

[Wes Huff @WesleyLHuff]

This Easter, I invite you to look at Jesus, consider what he said and did, and ask for yourself what I believe is the most important question you will ever answer: Did he really leave behind an empty tomb? And if he did, what does that mean for you?

This video was made possible and in collaboration with my friends at @ChildlikeMedia.

[Matt Dancho (Business Science) @mdancho84]

Principal Component Analysis (PCA) is the gold standard in dimensionality reduction.

But PCA is hard to understand for beginners.

Let me destroy your confusion:

[Matt Dancho (Business Science) @mdancho84]

The 3 types of machine learning (that every data scientist should know).

In 3 minutes I'll eviscerate your confusion. Let's go: 🧵

[Matt Tabinor ن @Tabsinator]

@ThePhDPlace Quoting a p value without an effect size (and confidence intervals … )

[Prof Lennart Nacke, PhD @acagamic]

Everybody starts their paper with definitions.

It is a mistake.

If nobody is suffering, nobody cares.

I reject any draft that leads with history instead of pain.

Here is the 3-question framework I use to fix boring intros:

[ASN Publications @asnpublications]

Ethnic differences in chronic kidney disease (CKD) progression remain understudied. This #ASNCJASN study found that CKD progression was faster in a Korean cohort than in a US cohort, with Asian participants in both cohorts showing similar eGFR decline rates. Read more: https://t.co/OiK7Hm2O9c